EAN 2021 | Broadening the applications of CBD in epilepsy syndromes

The therapeutic potential of cannabinoids has long been recognized, but only recently has high quality evidence from clinical trials begun to emerge that supports their use in specific indications. In 2018, cannabidiol (CBD), one of the prominent phytocannabinoids, was approved for the treatment of Dravet syndrome and Lennox-Gastaut syndrome. Andreas Schulze-Bonhage, PhD, University Medical Center Freiburg, Freiburg im Breisgau, Germany, gives an overview of the current status of cannabinoids in the treatment of epilepsy syndromes and future prospects. Prof. Schulze-Bonhage highlights this as a promising and advancing field, with much potential to assess more compounds and wider applications. This interview took place during the European Academy of Neurology 2021 congress.